Hi Sunclouds -- none of us are in a position to recommend specific partnerships for CYDY since we don't have access to the boardroom. However, I would like to respond to your question by providing examples of "top tier" partnerships.
I don't want this to devolve in to a debate about Lenzilumab vs. Leronlimab. (And, both companies have an unfortunate tie to Shrkeli). I'm just suggesting that, since Covid, this company has entered in to some strong partnerships. Here is a financial partnership, where they raised money from five institutional health care funds.
https://ir.humanigen.com/news/news-details/20...fault.aspx
They then did a reverse split and uplisted to Nasdaq. (I'm also not here to debate reverse-splits.) I will just say....they are on Nasdaq and they are not out of cash.
Later, they announced partnerships in the Philippines and for distribution (Thermo-Fisher). Those announcements are with much stronger firms than ours. They also have a deal going with Gilead-Kite.
Then, they announced a partnership with the US Govt and OWS. Most recently, they issued the press release below.
https://s27.q4cdn.com/938944131/files/doc_new...e-2021.pdf
Again, we can debate the merits of the drug. I don't think the professionalism or the financial structure is up for debate.
That said, CYDY would have significantly leapfrogged them in every area if CD12 had hit the primary endpoint. But...it didn't.
As of today....CYDY Market cap is $1.5 billion. HGEN is about $950 million. Maybe HGEN has "given up some of the upside" with these partnerships. But, they have likely exchanged that upside with risk mitigation.
And, I can't finish this post without saying.....NP's greatest sleight of hand was the Vyera deal. That deal stunk to high heaven then and it still does. Not only the quality of the partner, but the "fruits" of the deal to date. He has talked about the $95 million in milestones 100 times and we have yet to see the first $$. If Covid hadn't come along, that deal would have already been exposed as a complete "story" with no substance.
I don't want this to devolve in to a debate about Lenzilumab vs. Leronlimab. (And, both companies have an unfortunate tie to Shrkeli). I'm just suggesting that, since Covid, this company has entered in to some strong partnerships. Here is a financial partnership, where they raised money from five institutional health care funds.
https://ir.humanigen.com/news/news-details/20...fault.aspx
They then did a reverse split and uplisted to Nasdaq. (I'm also not here to debate reverse-splits.) I will just say....they are on Nasdaq and they are not out of cash.
Later, they announced partnerships in the Philippines and for distribution (Thermo-Fisher). Those announcements are with much stronger firms than ours. They also have a deal going with Gilead-Kite.
Then, they announced a partnership with the US Govt and OWS. Most recently, they issued the press release below.
https://s27.q4cdn.com/938944131/files/doc_new...e-2021.pdf
Again, we can debate the merits of the drug. I don't think the professionalism or the financial structure is up for debate.
That said, CYDY would have significantly leapfrogged them in every area if CD12 had hit the primary endpoint. But...it didn't.
As of today....CYDY Market cap is $1.5 billion. HGEN is about $950 million. Maybe HGEN has "given up some of the upside" with these partnerships. But, they have likely exchanged that upside with risk mitigation.
And, I can't finish this post without saying.....NP's greatest sleight of hand was the Vyera deal. That deal stunk to high heaven then and it still does. Not only the quality of the partner, but the "fruits" of the deal to date. He has talked about the $95 million in milestones 100 times and we have yet to see the first $$. If Covid hadn't come along, that deal would have already been exposed as a complete "story" with no substance.
2
